Medicines Co (MDCO.OQ) Quote| Reuters.com
Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

33.26USD
24 Jun 2016
Change (% chg)

$-1.28 (-3.71%)
Prev Close
$34.54
Open
$33.16
Day's High
$34.39
Day's Low
$33.16
Volume
550,133
Avg. Vol
298,167
52-wk High
$43.78
52-wk Low
$25.50

MDCO.OQ

Chart for MDCO.OQ

About

The Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $2,330.61
Shares Outstanding(Mil.): 70.07
Dividend: --
Yield (%): --

Financials

  MDCO.OQ Industry Sector
P/E (TTM): -- 32.69 34.11
EPS (TTM): -4.69 -- --
ROI: -20.38 15.00 14.23
ROE: -38.12 16.08 15.46

BRIEF-Medicines Co announces initiation of phase II study for its investigational anesthetic

* Medicines Company announces initiation of phase II study for its investigational anesthetic, ABP-700

Jun 14 2016

BRIEF-The Medicines Company prices $350 million of convertible notes

* Says priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023

Jun 06 2016

BRIEF-Medicines Co intends to offer $350 mln of convertible notes

* The medicines company announces intention to offer $350 million of convertible notes

Jun 06 2016

BRIEF-Medicines Co completes patient enrollment for Orion-1 study of PCSK9SI

* Completes patient enrollment for Orion-1 study of PCSK9SI Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 02 2016

UK drugs watchdog warns it will struggle if Britain leaves EU

LONDON A British vote to leave the European Union would disrupt and could well delay the approval of new drugs, leaving UK regulators struggling to cope, the chairman of the country's medicines watchdog said on Monday.

May 23 2016

UK drugs watchdog warns it will struggle if Britain leaves EU

LONDON, May 23 A British vote to leave the European Union would disrupt and could well delay the approval of new drugs, leaving UK regulators struggling to cope, the chairman of the country's medicines watchdog said on Monday.

May 23 2016

BRIEF-Medicines expects to incur about $18 mln-$22 mln of pre-tax charges

* Estimates it will incur approximately $18 million to $22 million of pre-tax charges primarily during q2 of 2016 - sec filing

May 13 2016

Medicines Co to sell cardiovascular drugs to Italy's Chiesi

The Medicines Co said on Monday it has agreed to sell three of its cardiovascular drugs to Italy's Chiesi Farmaceutici SpA for up to $792 million, as the U.S. company looks to raise money for drug development.

May 09 2016

UPDATE 2-Medicines Co to sell cardiovascular drugs to Italy's Chiesi

May 9 The Medicines Co said on Monday it has agreed to sell three of its cardiovascular drugs to Italy's Chiesi Farmaceutici SpA for up to $792 million, as the U.S. company looks to raise money for drug development.

May 09 2016

BRIEF-The Medicines Co to divest non-core cardiovascular assets

* Deal will result in anticipated reduction in annual SG&A and related research and development expenses of between $65 million and $80 million

May 09 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.